Initial Therapeutic Approaches to Patients with Multiple Myeloma

Hadi E. Berbari, Shaji K. Kumar

Research output: Contribution to journalReview articlepeer-review


Multiple Myeloma (MM) is part of a spectrum of plasma cell disorders that may result in end organ damage. MM is subclassified into high and standard risk based on cytogenetic and laboratory markers. The treatment of newly diagnosed multiple myeloma is constantly changing with the advent of novel therapies. Recent advances in therapies have resulted in longer time to remission and overall survival. the introduction of targeted therapy with monoclonal antibodies such as Daratumumab has improved stringent complete response to 39%. In this review, we outline the current approach to diagnosis, prognosis, and management of newly diagnosed multiple myeloma in both transplant eligible and ineligible patients

Original languageEnglish (US)
Pages (from-to)3694-3711
Number of pages18
JournalAdvances in Therapy
Issue number7
StatePublished - Jul 2021


  • Multiple myeloma
  • Therapeutic approaches

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Initial Therapeutic Approaches to Patients with Multiple Myeloma'. Together they form a unique fingerprint.

Cite this